PCRX · Categories · Downgrades
PCRX - Analyst downgrades
Pacira BioSciences Inc. (PCRX) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for PCRX
- Pacira BioSciences downgraded by Truist with a new price targetTruist downgraded Pacira BioSciences from Buy to Sell and set a new price target of $8.00 from $30.00 previously
- Pacira BioSciences downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Pacira BioSciences from Overweight to Neutral and set a new price target of $11.00 from $42.00 previously
- Pacira BioSciences downgraded by JP Morgan with a new price targetJP Morgan downgraded Pacira BioSciences from Overweight to Underweight and set a new price target of $10.00 from $45.00 previously
- Pacira BioSciences downgraded by Raymond JamesRaymond James downgraded Pacira BioSciences from Outperform to Mkt Perform
- Pacira BioSciences downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded Pacira BioSciences from Outperform to Sector Perform and set a new price target of $14.00 from $37.00 previously
- Pacira BioSciences downgraded by Barclays with a new price targetBarclays downgraded Pacira BioSciences from Overweight to Equal Weight and set a new price target of $25.00 from $38.00 previously
- Pacira Pharma downgraded by Northland Capital with a new price targetNorthland Capital downgraded Pacira Pharma from Outperform to Market Perform and set a new price target of $75.00 from $72.00 previously
- Pacira Pharma downgraded by SVB LeerinkSVB Leerink downgraded Pacira Pharma from Outperform to Mkt Perform and set a new price target of $75